Modeling, chemistry, and biology of the benzolactam analogues of indolactam V (ILV). 2. Identification of the binding site of the benzolactams in the CRD2 activator-binding domain of PKCδ and discovery of an ILV analogue of improved isozyme selectivity

Journal of Medicinal Chemistry

Volumn 40, Issue 9, 1997, Pages 1316-1326

  Kozikowski, Alan P ^a   Wang, Shaomeng ^a   Ma, Dawei ^b   Yao, Jiangchao ^b   Ahmad, Shakeel ^c   Glazer, Robert I ^c   Bogi, Krisztina ^d   Acs, Peter ^d   Modarres, Shayan ^d   Lewin, Nancy E ^d   Blumberg, Peter M ^d  

^a GEORGETOWN UNIVERSITY   (United States)

^b SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY   (China)

^c GEORGETOWN UNIVERSITY   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDOLACTAM V; LACTAM DERIVATIVE; PROTEIN KINASE C;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; BREAST CARCINOMA; DOWN REGULATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; SECOND MESSENGER;

ANTINEOPLASTIC AGENTS; BINDING SITES; BINDING, COMPETITIVE; BREAST NEOPLASMS; CELL DIVISION; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; FEMALE; HUMANS; HYDROGEN BONDING; INDOLES; ISOENZYMES; LACTAMS; LYNGBYA TOXINS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; MUTAGENESIS, SITE-DIRECTED; PROTEIN KINASE C; TUMOR CELLS, CULTURED;

EID: 15444345629     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm960875h     Document Type: Article

References (62)

1. Nishizuka, Y. The molecular heterogeneity of protein kinase C and its implications for cellular recognition. Nature 1988, 334, 661-65. Dekker, L. V.; Parker, P. J. Protein kinase C: a question of specificity. Trends Biochem. Sci. 1994, 19, 73-77. Protein Kinase C, Current Concepts and Future Perspectives; Lester, D. S., Epand, R. M., Eds.; Ellis Horwood Ltd.: New York, 1992. Basu, A. The potential of protein kinase C for anticancer treatment. Pharmacol. Ther. 1993, 59, 257-280. Glazer, R. I. Protein kinase C in neoplastic transformation and differentiation. In Protein Kinase C; Kuo, J. F., Ed.; Oxford Press: Oxford, England, 1994; pp 171-198.
2. Nishizuka, Y. The molecular heterogeneity of protein kinase C and its implications for cellular recognition. Nature 1988, 334, 661-65. Dekker, L. V.; Parker, P. J. Protein kinase C: a question of specificity. Trends Biochem. Sci. 1994, 19, 73-77. Protein Kinase C, Current Concepts and Future Perspectives; Lester, D. S., Epand, R. M., Eds.; Ellis Horwood Ltd.: New York, 1992. Basu, A. The potential of protein kinase C for anticancer treatment. Pharmacol. Ther. 1993, 59, 257-280. Glazer, R. I. Protein kinase C in neoplastic transformation and differentiation. In Protein Kinase C; Kuo, J. F., Ed.; Oxford Press: Oxford, England, 1994; pp 171-198.
3. Nishizuka, Y. The molecular heterogeneity of protein kinase C and its implications for cellular recognition. Nature 1988, 334, 661-65. Dekker, L. V.; Parker, P. J. Protein kinase C: a question of specificity. Trends Biochem. Sci. 1994, 19, 73-77. Protein Kinase C, Current Concepts and Future Perspectives; Lester, D. S., Epand, R. M., Eds.; Ellis Horwood Ltd.: New York, 1992. Basu, A. The potential of protein kinase C for anticancer treatment. Pharmacol. Ther. 1993, 59, 257-280. Glazer, R. I. Protein kinase C in neoplastic transformation and differentiation. In Protein Kinase C; Kuo, J. F., Ed.; Oxford Press: Oxford, England, 1994; pp 171-198.
4. Nishizuka, Y. The molecular heterogeneity of protein kinase C and its implications for cellular recognition. Nature 1988, 334, 661-65. Dekker, L. V.; Parker, P. J. Protein kinase C: a question of specificity. Trends Biochem. Sci. 1994, 19, 73-77. Protein Kinase C, Current Concepts and Future Perspectives; Lester, D. S., Epand, R. M., Eds.; Ellis Horwood Ltd.: New York, 1992. Basu, A. The potential of protein kinase C for anticancer treatment. Pharmacol. Ther. 1993, 59, 257-280. Glazer, R. I. Protein kinase C in neoplastic transformation and differentiation. In Protein Kinase C; Kuo, J. F., Ed.; Oxford Press: Oxford, England, 1994; pp 171-198.
5. Nishizuka, Y. The molecular heterogeneity of protein kinase C and its implications for cellular recognition. Nature 1988, 334, 661-65. Dekker, L. V.; Parker, P. J. Protein kinase C: a question of specificity. Trends Biochem. Sci. 1994, 19, 73-77. Protein Kinase C, Current Concepts and Future Perspectives; Lester, D. S., Epand, R. M., Eds.; Ellis Horwood Ltd.: New York, 1992. Basu, A. The potential of protein kinase C for anticancer treatment. Pharmacol. Ther. 1993, 59, 257-280. Glazer, R. I. Protein kinase C in neoplastic transformation and differentiation. In Protein Kinase C; Kuo, J. F., Ed.; Oxford Press: Oxford, England, 1994; pp 171-198.
6. Kozikowski, A. P.; Sato, K.; Basu, A.; Lazo, J. S. Synthesis and biological studies of simplified analogues of lyngbyatoxin A: use of an isoxazoline-based indole synthesis. Quest for protein kinase C modulators. J. Am. Chem. Soc. 1989, 111, 6228-6234. Kozikowski, A. P.; Shum, P. W.; Basu, A.; Lazo, J. S. Synthesis of structural analogues of lyngbyatoxin A and their evaluation as activators of protein kinase C. J. Med. Chem. 1991, 34, 2420-2430.
7. Kozikowski, A. P.; Sato, K.; Basu, A.; Lazo, J. S. Synthesis and biological studies of simplified analogues of lyngbyatoxin A: use of an isoxazoline-based indole synthesis. Quest for protein kinase C modulators. J. Am. Chem. Soc. 1989, 111, 6228-6234. Kozikowski, A. P.; Shum, P. W.; Basu, A.; Lazo, J. S. Synthesis of structural analogues of lyngbyatoxin A and their evaluation as activators of protein kinase C. J. Med. Chem. 1991, 34, 2420-2430.
8. Stabel, S.; Parker, P. J. Protein kinase C. Pharmacol. Ther. 1991, 51, 71-95. Cacace, A. M.; Guadagno, S. N.; Krauss, R. S.; Fabbro, D.; Weinstein, I. B. The epsilon isozyme of protein kinase C is an oncogene when overexpressed in rat fibroblasts. Oncogene 1993, 8, 2095-2104. Powis, G.; Kozikowski, A. P. Growth factor and oncogene signaling pathways as targets for rational anticancer drug development. Clin. Biochem. 1991, 24, 385-397.
9. Stabel, S.; Parker, P. J. Protein kinase C. Pharmacol. Ther. 1991, 51, 71-95. Cacace, A. M.; Guadagno, S. N.; Krauss, R. S.; Fabbro, D.; Weinstein, I. B. The epsilon isozyme of protein kinase C is an oncogene when overexpressed in rat fibroblasts. Oncogene 1993, 8, 2095-2104. Powis, G.; Kozikowski, A. P. Growth factor and oncogene signaling pathways as targets for rational anticancer drug development. Clin. Biochem. 1991, 24, 385-397.
10. Stabel, S.; Parker, P. J. Protein kinase C. Pharmacol. Ther. 1991, 51, 71-95. Cacace, A. M.; Guadagno, S. N.; Krauss, R. S.; Fabbro, D.; Weinstein, I. B. The epsilon isozyme of protein kinase C is an oncogene when overexpressed in rat fibroblasts. Oncogene 1993, 8, 2095-2104. Powis, G.; Kozikowski, A. P. Growth factor and oncogene signaling pathways as targets for rational anticancer drug development. Clin. Biochem. 1991, 24, 385-397.
11. Kazanietz, M. G.; Areces, L. B.; Bahador, A.; Mischak, H.; Goodnight, J.; Mushinski, F.; Blumberg, P. M. Characterization of ligand and substrate specificity for the calcium-dependent and calcium-independent PKC isozymes. Mol. Pharmacol. 1993, 44, 298-307.
12. Zhang, G.; Kazanietz, M. G.; Blumberg, P. M.; Hurley, J. H. Crystal structure of the Cys2 activator-binding domain of protein kinase Cd in complex with phorbol ester. Cell. 1995, 81, 917-924.
13. Merrill, A. H. Jr.; Sereni, A. M.; Stevens, V. L.; Hannun, Y. A.; Bell, R. M.; Kinkade, J. M. Jr. Inhibition of phorbol ester-dependent differentiation of human promyelocytic leukemic (HL-60) cells by sphinganine and other long-chain bases. J. Biol. Chem. 1986, 261, 12610-12615.
14. Yu, G.; Ahmad, S.; Aquine, A.; Fairchild, C. R.; Trepel, J. B.; Ohno, S.; Suzuki, K.; Tsuruo, T.; Cowan, K. H.; Glazer, R. I. Transfection with protein kinase C a confers increased multi-drug resistance to MCF-7 cells expressing P-glycoprotein. Cancer Commun. 1991, 3, 181-189.
15. Basu, A.; Kozikowski, A. P.; Sato, K.; Lazo, J. S. Cellular sensitization to cis-diamminedichloroplatinum(II) by novel analogues of the protein kinase C activator lyngbyatoxin A. Cancer Res. 1991, 51, 2511-2514.
16. Takashima, M.; Sakai, H. A new toxic substance, teleocidin produced by Streptomyces. Part I. Production, isolation, and chemical studies. Bull. Agric. Chem. Soc. Jpn. 1960, 24, 647-651.
17. Cardellina, J. H., II; Marner, F.-J.; Moore, R. E. Seaweed dermatitis: structure of lyngbyatoxin A. Science 1979, 204, 1193-1195.
18. Sakai, S.; Hitotsuyanagi, Y.; Aimi, N.; Pujiki, H.; Suganuma, M.; Sugimura, T.; Endo, Y.; Shudo, K. Absolute configuration of lyngbyatoxin A (teleocidin A-1) and teleocidin A-2. Tetrahedron Lett. 1986, 27, 5219-5220.
19. Sugimura, T.; Fujiki, H.; Mori, M.; Nakayasu, M.; Terada, M.; Umezawa, K.; Moore, R. E. Teleocidin: new naturally occurring tumor promoter. Carcinogenesis 1982, 7, 69-73.
20. Moore, R. E. Toxins, anticancer agents, and tumor promoters from marine prokaryotes. Pure Appl. Chem. 1982, 54, 1919-1934; Irie, K.; Koshimizu, K. Chemistry of indole alkaloid tumor promoter teleocidins. Comments Agric. Food Chem. 1993, 3, 1-25. Irie, K.; Koshimizu, K. Structure-activity studies of indole alkaloid tumor promoters. Memoirs of the College of Agriculture, Kyoto University, No. 132, 1988.
21. Moore, R. E. Toxins, anticancer agents, and tumor promoters from marine prokaryotes. Pure Appl. Chem. 1982, 54, 1919-1934; Irie, K.; Koshimizu, K. Chemistry of indole alkaloid tumor promoter teleocidins. Comments Agric. Food Chem. 1993, 3, 1-25. Irie, K.; Koshimizu, K. Structure-activity studies of indole alkaloid tumor promoters. Memoirs of the College of Agriculture, Kyoto University, No. 132, 1988.
22. Moore, R. E. Toxins, anticancer agents, and tumor promoters from marine prokaryotes. Pure Appl. Chem. 1982, 54, 1919-1934; Irie, K.; Koshimizu, K. Chemistry of indole alkaloid tumor promoter teleocidins. Comments Agric. Food Chem. 1993, 3, 1-25. Irie, K.; Koshimizu, K. Structure-activity studies of indole alkaloid tumor promoters. Memoirs of the College of Agriculture, Kyoto University, No. 132, 1988.
23. Endo, Y.; Hasegawa, M.; Itai, A.; Shudo, K.; Tori, M.; Asakawa, Y.; Sakai, S. Tumor promoters in two conformational states in solution. Stereochemistry of (±)-Indolactam-V. Tetrahedron Lett. 1985, 26, 1069-1072.
24. Endo, Y.; Ohno, M.; Hirano, M.; Itai, A.; Shudo, K. Synthesis, conformation, and biological activity of teleocidin mimics, benzolactams. Problem in structure-activity studies of teleocidins. J. Am. Chem. Soc. 1996, 118, 1841-1855.
25. Itai, A.; Kato, Y.; Tomioka, N.; Iitaka, Y.; Endo, Y.; Hasegawa, M.; Shudo, K.; Fujiki, H.; Sakai, S. A receptor model for tumor promoters: rational superposition of teleocidins and phorbol esters. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 3688-3692.
26. Rando, R.; Kishi, Y. Structural basis of protein kinase C activation by diacylglycerols and tumor promoters. Biochemistry 1992, 31, 2211-2218.
27. Thomson, C.; Wilkie, J. The conformations and electrostatic potential maps of phorbol esters, teleocidins and ingenols. Carcinogenesis 1989, 10, 531-540.
28. Wender, P. A.; Cribbs, C. M.; Koehler, K. F.; Sharkey, N. A.; Herald, C. L.; Kamano, Y.; Pettit, G. R.; Blumberg, P. M. Proc. Nat. Acad. Sci. U.S.A. 1988, 86, 7197-7201.
29. Blumberg, P. M.; Lewin, N. E.; Wang, S. Unpublished work.
30. Kozikowski, A. P.; Ma, D.; Pang, Y.-P.; Shum, P.; Likic, V.; Mishra, P. K.; Macura, S.; Basu, A.; Lazo, J. S.; Ball, R. G. Synthesis, molecular modeling, 2-D-NMR, and biological evaluation of ILV mimics as potential modulators of protein kinase C. J. Am. Chem. Soc. 1993, 115, 3957-3965.
31. Irie, K.; Hagiwara, N.; Tokuda, H.; Koshimizu, K. Structure-activity studies of the indole alkaloid tumor promoter teleocidins. Carcinogenesis 1987, 8, 547-552 and 963-965.
32. Irie, I.; Okuno, S.; Kajiyama, S.; Koshimizu, K.; Nishino, H.; Iwashima, A. Quantitative structure-activity studies on indole alkaloid tumor promoter indolactam congeners. Carcinogenesis 1991, 12, 1883-1886.
33. Kozikowski, A. P.; Ma, D.; Du, L.; Lewin, N. E.; Blumberg, P. M. Effect of alteration of the heterocyclic nucleus of ILV on its isozyme selectivity for PKC. Palladium-catalyzed route to the benzofuran analogues of ILV. J. Am. Chem. Soc. 1995, 117, 6666-6672. Kozikowski, A. P.; Ma, D.; Du, L.; Lewin, N. E.; Blumberg, P. M. Synthesis of the benzofuran analogue of ILV, a new protein kinase C (PKC) activator. Bioorg. Med. Chem. Lett. 1994, 4, 637-640.
34. Kozikowski, A. P.; Ma, D.; Du, L.; Lewin, N. E.; Blumberg, P. M. Effect of alteration of the heterocyclic nucleus of ILV on its isozyme selectivity for PKC. Palladium-catalyzed route to the benzofuran analogues of ILV. J. Am. Chem. Soc. 1995, 117, 6666-6672. Kozikowski, A. P.; Ma, D.; Du, L.; Lewin, N. E.; Blumberg, P. M. Synthesis of the benzofuran analogue of ILV, a new protein kinase C (PKC) activator. Bioorg. Med. Chem. Lett. 1994, 4, 637-640.
35. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J. T.; Bokesch, H.; Kenney, S.; Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 1990, 82, 1107-1112. Ahmad, S; Glazer, R. I. Expression of the antisense cDNA to protein kinase Cα attenuates resistance in doxorubicin-resistant MCF-7 breast carcinoma cells. Mol. Pharmacol. 1993, 43, 858-862.
36. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J. T.; Bokesch, H.; Kenney, S.; Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 1990, 82, 1107-1112. Ahmad, S; Glazer, R. I. Expression of the antisense cDNA to protein kinase Cα attenuates resistance in doxorubicin-resistant MCF-7 breast carcinoma cells. Mol. Pharmacol. 1993, 43, 858-862.
37. Jeffrey, A. M.; Liskamp, R. M. Computer-assisted molecular modelling of tumour promoters: rationale for the activity of phorbol esters, teleocidin B, and aplysiatoxin. Proc. Natl. Acad. Sci. U.S.A. 1986, 83, 241-245.
38. Wender, P. A.; Koehler, K. F.; Sharkey, N. A.; Dell'Aquila, M. L.; Blumberg, P. M. Analysis of the phorbol ester pharmacophore on protein kinase C as a guide to the rational design of new classes of analogs. Proc. Natl. Acad. Sci. U.S.A. 1986, 83, 4214-4218.
39. Nakamura, H.; Kishi, Y.; Pajares, M. A.; Rando, R. R. Structural basis of protein kinase C activation by tumour promoters. Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 9672-9676.
40. Leli, U.; Hauser, G.; Froimowitz, M. Requirements for the activation of protein kinase C: comparison of the molecular geometries of phorbol and diacylglycerols. Mol. Pharmacol. 1990, 37, 286-295.
41. Kazanietz, M. G.; Wang, W.; Milne, G. W. A.; Lewin, N. E.; Liu, H. L.; Blumberg, P. M. Residues in the second cysteine-rich region of PKC relevant to phorbol ester binding as revealed by site-directed mutagenesis. J. Biol. Chem. 1995, 270, 21852-21859.
42. Blumberg, P. M.; Lewin, N. E.; et al. Manuscript in preparation.
43. Wang, S.; et al. Manuscript in preparation.
44. Wang, S.; Milne, G. W. A.; Nicklaus, M. C.; Marquez, V. E.; Lee, J.; Blumberg, P. M. Protein kinase C. Modeling of the binding site and prediction of binding constants. J. Med. Chem. 1994, 37, 1326-1338.
45. Blumberg, P. M.; et. al. Unpublished results.
46. Irie, I.; Okuno, S.; Kajiyama, S.; Koshimizu, K.; Nishino, H.; Iwashima, A. Quantitative structure-activity studies on indole alkaloid tumor promoter indolactam congeners. Carcinogenesis 1991, 12, 1883-1886.
47. McKennon, M. J.; Meyers, A. I.; Drauz, K.; Schwarm, M. A convenient reduction of amino acids and their derivatives. J. Org. Chem. 1993, 58, 3568-3571.
48. Kogan, T. P.; Somers, T. C.; Venuti, M. C. A regio-and stereocontrolled total synthesis of (-)-indolactam-V. Tetrahedron 1990, 46, 6623-6632.
49. Endo, Y.; Shudo, K.; Itai, A.; Hasegawa, M.; Sakai, S. Synthesis and stereochemistry of indolactam-V, an active fragment of teleocidins. Structural requirements for tumor-promoting activity. Tetrahedron 1986, 42, 5905-5924.
50. Brewster, R. Q. p-Iodoaniline. Organic Syntheses; Wiley: New York, 1943; Collect. Vol. 2, pp 347-348.
51. Kikukawa, K.; Abe, A.; Wada, F.; Matsuda, T. Palladium-catalyzed reaction of 4′-iodobenzocrown ethers with acetylenes. Convenient synthesis of alkyl-substituted benzocrown ethers and bis(benzocrown ethers) via alkynyl-substituted benzocrown ethers. Bull. Chem. Soc. Jpn. 1983, 57, 961-962.
52. Endo, Y.; Imada, T.; Yamaguchi, K.; Shudo, K. Conformational states of indolactams: Structures of 13-N-Desmethylindolactam-V and 13-O-indolactam-V. Heterocycles 1994, 39, 571-579.
53. QUANTA, a molecular modeling system, is supplied by Molecular Simulations Inc., 200 Fifth Ave., Waltham, MA 01803-5279.
54. Brooks, B. R.; Bruccoleri, R. E.; Olafson, B. D.; States, D. J.; Swaminathan, S.; Karplus, M. CHARMM: A program for macromolecular energy, minimization, and dynamics calcula tions. J. Comput. Chem. 1983, 4, 187-217.
55. Jorgensen, W. L.; Chandrasekhar, J.; Madura, J. D.; Impey, R. W.; Klein, M. L. Comparison of simple potential functions for simulating liquid water. J. Chem. Phys. 1983, 79, 926-935.
56. van Gunsteren, W. F.; Berendsen, H. J. C. Algorithms for macromolecular dynamics and constraint dynamics. Mol. Phys. 1977, 34, 1311-1327.
57. Harada, H.; Sakabe, N.; Hirata, Y.; Tomiie, Y.; Nitta, I. The X-ray structure determination of dihydroteleocidin B monobromoacetate. Bull. Chem. Soc. Jpn. 1966, 39, 1773-1775. The X-ray coordinates can be found in the Cambridge Structural Database under the code name TLOBDH10.
58. Gaussian 92/DFT, Revision G.4: Frisch, M. J.; Truck, G. W.; Schlegel, H. B.; Robb, M. A.; Head-Gordon, M.; Replogle, E. S.; Gomperts, C.; Martin, R. L.; Fox, D. J.; Defrees, D. J.; Baker, J.; Stewart, J. J. P.; Pople, J. A., Gaussian, Inc., Pittsburgh, PA, 1993.
59. The HINT program is supplied by eduSoft, LC, P.O. Box 1811, Ashland, VA 23005. Kellogg, G. E.; Joshi, G. S.; Abraham, D. J. New tools for modeling and understanding hydrophobicity and hydrophobic interactions. Med. Chem. Res. 1992, 1, 444-453. Meng, E. C.; Kuntz, I. D.; Abraham, D. J.; Kellogg, G. E. Evaluating docked complexes with the HINT exponential function and empirical atomic hydrophobicities. J. Compt.-Aided Mol. Des. 1994, 8, 299-306.
60. The HINT program is supplied by eduSoft, LC, P.O. Box 1811, Ashland, VA 23005. Kellogg, G. E.; Joshi, G. S.; Abraham, D. J. New tools for modeling and understanding hydrophobicity and hydrophobic interactions. Med. Chem. Res. 1992, 1, 444-453. Meng, E. C.; Kuntz, I. D.; Abraham, D. J.; Kellogg, G. E. Evaluating docked complexes with the HINT exponential function and empirical atomic hydrophobicities. J. Compt.-Aided Mol. Des. 1994, 8, 299-306.
61. The HINT program is supplied by eduSoft, LC, P.O. Box 1811, Ashland, VA 23005. Kellogg, G. E.; Joshi, G. S.; Abraham, D. J. New tools for modeling and understanding hydrophobicity and hydrophobic interactions. Med. Chem. Res. 1992, 1, 444-453. Meng, E. C.; Kuntz, I. D.; Abraham, D. J.; Kellogg, G. E. Evaluating docked complexes with the HINT exponential function and empirical atomic hydrophobicities. J. Compt.-Aided Mol. Des. 1994, 8, 299-306.
62. Chem-X is a product of Chemical Design Ltd., Roundway House, Cromwell Park, Chipping Norton, Oxon OX7 5SR, U.K.